Kincell Bio announced the completion of a $22 million round led by new investor NewSpring Capital through its dedicated healthcare strategy NewSpring Healthcare. The funding round was also led by existing investor Kineticos Life Sciences.
Kincell Bio is a scientifically focused cell therapy development and manufacturing company. This funding round marks a significant milestone in Kincell Bio’s mission to transform the delivery of advanced cell therapies to patients worldwide.
Kincell Bio’s platform provides clients with a personalized, responsive, and expert-driven approach to process development and manufacturing from early clinical to pivotal supply and commercial launch, ensuring rapid timelines without compromising on quality.
What the funding will be used for: This funding will accelerate Kincell Bio’s expansion of its cGMP capabilities, enhance its process development services, and support the development of innovative solutions tailored to emerging cell therapy companies. And with the cell and gene therapy market projected to surpass $23 billion globally by 2028, this infusion of capital positions Kincell Bio as a leader in the next generation of biomanufacturing.
New board member: As part of this strategic partnership, Pete Buzy, former President and CEO of Catalent Cell & Gene Therapy, has been appointed to Kincell Bio’s Board of Directors.
Buzy brings over two decades of leadership in advanced biologics, having played a key role in building Catalent’s cell and gene therapy platform into one of the industry’s most advanced development and manufacturing organizations. Before that, he led one of NewSpring Healthcare’s portfolio companies, Paragon Bioservices, a contract development and manufacturing company focused on gene therapies. His appointment underscores Kincell Bio’s commitment to operational excellence and long-term growth.
KEY QUOTES:
“We are excited to partner with the experienced team at NewSpring and to have them join our existing investors to support Kincell Bio, as we continue to scale our operations and deliver high-quality, flexible, and scalable solutions to our partners in the cell therapy space. Adding Pete Buzy to our board brings unparalleled insight into the complexities and opportunities within the advanced therapies sector and we are excited to partner with him and the NewSpring team.”
Mark R. Bamforth, CEO of Kincell Bio
“Kincell Bio is bringing the right focus, flexibility, and scientific rigor to a market that’s evolving rapidly. I’m looking forward to supporting this team as they expand their capabilities for the next generation of cell therapy innovators. My history with NewSpring goes back more than a decade, including our work together at Paragon Bioservices, and I’ve seen firsthand how the right partnership can accelerate growth.”
Pete Buzy
“Cell therapy is revolutionizing medicine, and we see Kincell Bio as a uniquely positioned CDMO with a clear vision and a leadership team capable of executing. Our investment and Pete’s Board appointment reflect our confidence in the company’s potential to play a pivotal role in shaping the future of cell therapy manufacturing, and further highlights NewSpring’s approach of pairing capital with strategic and operating expertise.”
Kapila Ratnam, Ph.D., NewSpring General Partner with over 20 years of experience in the healthcare industry
“We are thrilled to welcome NewSpring as a trusted partner. Their shared commitment to mission‑driven investing perfectly aligns with our vision of supporting innovative cell therapy companies. We look forward to working alongside Mark Bamforth and the entire Kincell Bio team to accelerate the development and delivery of life‑saving therapies, ensuring patients benefit from these breakthroughs as quickly and safely as possible.”
Shailesh Maingi, Founder and Managing Partner at Kineticos Life Sciences
